Figure 3C shows that compared with PRAD patients without EMC2 mutations, those with EMC2 mutations had decreased OS (p = 3.384e-4), disease-free survival (p = 1.137e-3), and progression-free survival (p = 8.209e-4), whereas the disease-specific survival rate (p = 2.81e-7) was particularly poor. In breast cancer patients, survival was not affected by the above mentioned mutations. Considering the number of clinical samples, the effect of EMC2 structural mutations on breast cancer prognosis requires further analysis. This evidence concerns the gene EMC2 and prostate adenocarcinoma.